Study details
Enrolling now
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT IDNCT07392242ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
60+
Locations
7 sites in NJ, NY
What this study is about
This Phase 2 study is testing Azacitidine in people with leukemia. The primary outcome being measured is Event free survival.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVsubcutaneous
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
azacitidine, ivosidenib, venetoclax
Drug routes
injection, subcutaneous, oral (Oral Tablet), oral
Endpoints
Primary: Event free survival
Body systems
Oncology